Pulmonary Cell News 5.49 December 15, 2016 | |
| |
TOP STORYResearchers studied the biological role of SIRT4 in lung cancer cell lines transfected with SIRT4 plasmid or SIRT4-siRNA. SIRT4 inhibited lung cancer cell proliferation, blocked the cell cycle and repressed cell invasion and migration. [Oncogene] Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Alternative Progenitor Lineages Regenerate the Adult Lung Depleted of Type II Cells Investigators showed that alveolar epithelial type II (AEC2) cells, a progenitor for AEC1 cells are depleted in adult mice exposed to neonatal hypoxia or hyperoxia. Airway cells expressing SP-C and ABCA3, alveolar pod cells expressing KRT5, and pulmonary fibrosis was observed when these mice were infected with a sublethal dose of HKx31, H3N2 influenza A virus. [Am J Respir Cell Mol Biol] Abstract GS-5759 is a bifunctional ligand composed of a quinolinone-containing pharmacophore found in several β2-adrenoceptor agonists, including indacaterol, linked covalently to a phosphodiesterase 4 inhibitor related to GSK 256066 by a pent-1-yn-1-ylbenzene spacer. GS-5759 had similar affinity for PDE4B1 and the native β2-adrenoceptor expressed on BEAS-2B human airway epithelial cells. [J Pharmacol Exp Ther] Abstract | Full Article Researchers investigated whether ulinastatin attenuates acute lung injury through the inhibition of high-mobility group box 1 expression and to elucidate the underlying molecular mechanisms. [Int J Mol Med] Abstract LUNG CANCERNanosomes Carrying Doxorubicin Exhibit Potent Anticancer Activity against Human Lung Cancer Cells Scientists described the development and testing of a novel exosomes-gold nanoparticles-based therapeutic delivery system -‘nanosomes’- for lung cancer therapy. [Sci Rep] Full Article MiR-150 Promotes Cellular Metastasis in Non-Small Cell Lung Cancer by Targeting FOXO4 The authors revealed that the critical pro-metastatic role of microRNA-150 (miR-150) in the regulation of epithelial-mesenchymal-transition through down-regulation of FOXO4 in non-small cell lung cancer. [Sci Rep] Full Article Scientists showed that epidermal growth factor (EGF) inhibited proliferation and promotes programmed cell death in non-small cell lung cancer cells. In A549 cells, EGF increased redox factor-1 (Ref-1) expression and the association of Ref-1 with zinc finger-containing transcriptional regulator via activation of p22phox, RAC1, and an NADPH oxidase subunit. [Oncotarget] Full Article Researchers investigated the role of astragaloside IV in the chemoresistance to cisplatin in non-small cell lung cancer (NSCLC) cells. They established astragaloside IV-suppressed NSCLC cell lines including A549, HCC827, and NCI-H1299 and evaluated their sensitivity to cisplatin in vitro. [Cell Physiol Biochem] Full Article The authors investigated the inhibitory effects of delphinidin on vascular endothelial growth factor (VEGF) expression, an important factor involved in angiogenesis and tumor progression, in A549 human lung cancer cells. [Oncol Rep] Abstract | |
| |
REVIEWSDevelopmental Pathways in Lung Regeneration The authors outline the way that basic studies into lung developmental biology are now being applied to lung regeneration, opening up new avenues of research that may ultimately be harnessed for treatments of lung disease. [Cell Tissue Res] Abstract Visit our reviews page to see a complete list of reviews in the pulmonary cell research field. | |
| |
SCIENCE NEWSSpectrum Pharmaceuticals Highlights Promising Preclinical Data Evaluating Poziotinib in Lung Cancer Spectrum Pharmaceuticals announced the oral presentation of data from a preclinical study evaluating poziotinib in lung cancer by scientists from MD Anderson Cancer Center. [Press release from Spectrum Pharmaceuticals, Inc. discussing research presented at the 17th International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer, Vienna] Press Release | |
| |
INDUSTRY NEWSCancer Research UK, Cancer Research Technology, and Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide product platform, have announced an agreement to trial a first-in-class drug for cancers of high unmet need. [Cancer Research UK] Press Release DelMar Pharmaceuticals, Inc. announced that it received a Notice of Allowance from the U.S. Patent and Trademark Office for United States Patent Application Serial No. 13/933,844 entitled, “Improved Analytical Methods for Analyzing and Determining Impurities in Dianhydrogalactitol.” [DelMar Pharmaceuticals, Inc.] Press Release | |
| |
POLICY NEWSCanada’s Government Scientists Get Antimuzzling Clause in Contract Scientists working for the Canadian government have successfully negotiated a clause in their new contract that guarantees their right to speak to the public and the media about science and their research, without needing approval from their managers. [ScienceInsider] Editorial In Canada, Case Spurs Concern over Misconduct Secrecy In early 2013, scientists working in a laboratory led by a prominent cancer researcher at the University of British Columbia (UBC) in Vancouver, Canada, were getting worried. They were unable to reproduce results from several of the researcher’s experiments, and suspected some of the original work was fraudulent. An investigation by UBC ultimately confirmed their fears: In 2014, investigators identified 29 instances of scholarly misconduct, 16 of them “serious,” including falsification and fabrication of data, according to university correspondence obtained by Retraction Watch. [ScienceInsider] Editorial Is Donald Trump Pushing More Scientists towards Political Activism? Around the world, individual researchers and representatives of scientific societies are signing letters of protest or advice, offering to counsel Trump’s transition team and ramping up efforts to communicate the value of science to the public. [Nature News] Editorial
| |
EVENTSNEW Translational Opportunities in Stem Cell Research Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW PhD Positions – Heart and Lung Research (Max Planck Institute for Heart and Lung Research) NEW Postdoctoral Position – Cancer Epigenetics (Gustave Roussy Cancer Campus) Postdoctoral Position – Targeted Approaches to Lung Cancers (University of California San Francisco) Post-Doctoral Research Fellow – Neurobiology (Institut of Molecular Biology) Assistant Professor – Molecular Therapeutics of Cancer (Dartmouth College) Postdoctoral Research Assistant/Associate(s) (University of Cambridge) Postdoctoral Position – Heart, Lung and Blood Vascular Medicine (University of Pittsburgh) Postdoctoral Research Fellow – Cancer GeneticsEpigenetics (Fred Hutchinson Cancer Research Center) Postdoctoral Researcher – Lung Cancer (Northwestern University) Postdoctoral Fellow – Lung Biology (Boston University) Cell Biologist – Pulmonary Vascular Signaling (University of Maryland) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Pulmonary Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|